Rocket Doctor CEO, Dr. Essam Hamza, talks to Cantech Letter

Rocket Doctor (Rocket Doctor Stock Quote, Chart, News, Analysts, Financials CSE:AIDR) CEO Dr. Essam Hamza says the company’s AI-driven clinical tools are entering a commercialization phase as health systems look for technology that can reduce administrative workloads, improve triage accuracy and expand doctors’ patient capacity.

In an interview posted November 10 on the Cantech Letter YouTube channel, Hamza told Ticker Take host Jon Erlichman that Rocket Doctor’s platform is designed to support the full patient journey, from initial symptom assessment to post-visit monitoring.

He spoke with Erlichman during the 2025 Cantech Investment Conference in Toronto on October 9.

Hamza, a family physician with more than 25 years of clinical experience, joined Rocket Doctor AI two years ago and said the company has spent the past 18 months preparing its suite of tools for market adoption. He described the core product as an “AI nurse” capable of calling patients, gathering history, assessing symptoms and triaging whether they need emergency care or can safely wait for an appointment.

JON ERLICHMAN SITS DOWN WITH DR. ESSAM HANZA AT CANTECH 25

The system sends a structured history, suggested differential diagnoses, and recommended lab tests to physicians ahead of the visit, then supports doctors during the appointment by handling documentation and routine administrative tasks. After visits, the platform continues to check in with patients, helping manage chronic conditions or post-discharge recovery to prevent repeat hospitalizations.

Hamza said this “full continuum of care, AI-powered tools really is the future of healthcare efficiency.”

He said that the model works because it solves problems for what he called the three P’s: patients, practitioners and payers.

Patients gain 24/7 access and clearer direction when dealing with urgent issues. Physicians reduce paperwork and increase capacity, with Hamza estimating that a typical panel could expand from 2,000 to 10,000 patients using Rocket Doctor’s tools. Payers benefit from the resulting efficiency.

He also pointed to the company’s recent acquisition of a cross-border subsidiary operating a “Shopify for doctors,” giving practitioners a digital storefront where they can work flexibly without managing software, billing systems or contract logistics.

Rocket Doctor takes a percentage of platform revenue, which Hamza said averages about $17 per visit in Canada, while U.S. practitioners generate roughly US$18 per visit. For the AI-nurse workflow, the company uses a subscription model that charges doctors about $100 to $150 per month.

Hamza said adoption is being driven by governments and health agencies facing rising demand and constrained clinical resources. He predicted that AI-based triage will become mandatory within the next decade as emergency departments and clinics increasingly require pre-visit screening. He said both Canadian provinces and U.S. states are beginning to fund this category of technology, adding that Rocket Doctor expects to announce additional government grants as the market accelerates.

-30-